TOVX (Theriva Biologics) Cyclically Adjusted Book per Share: $-10.10 (As of Mar. 2026)


TOVX Theriva Biologics Inc TOVX
26 GF Score
Price $0.25
! 3 Warning Signs
View Full Analysis

What is Theriva Biologics Cyclically Adjusted Book per Share?

Theriva Biologics TOVX +0.16% 26 Cyclically Adjusted Book per Share is $-10.10 as of Mar. 2026. GuruFocus rates TOVX with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Theriva Biologics's adjusted book value per share for the three months ended in Mar. 2026 was $0.336. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-10.10 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Theriva Biologics's average Cyclically Adjusted Book Growth Rate was -110.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -70.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -55.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -35.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Theriva Biologics was 28.20% per year. The lowest was -70.80% per year. And the median was -16.55% per year.

As of today (2026-07-03), Theriva Biologics's current stock price is $0.251. Theriva Biologics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $-10.10. Theriva Biologics's Cyclically Adjusted PB Ratio of today is .


Theriva Biologics  (AMEX:TOVX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Theriva Biologics Cyclically Adjusted Book per Share Related Terms


Theriva Biologics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Theriva Biologics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theriva Biologics Cyclically Adjusted Book per Share Chart

Theriva Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 654.08 458.97 230.13 86.95 11.37

Theriva Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.12 153.68 66.49 11.37 -10.10

TOVX vs OSRH, PBM, PHIO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Theriva Biologics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Cyclically Adjusted PB Ratio falls into.


TOVX
26GF Score
Theriva Biologics Inc TOVX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theriva Biologics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theriva Biologics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.336/330.2130*330.2130
=0.336

Current CPI (Mar. 2026) = 330.2130.

Theriva Biologics Quarterly Data

Book Value per Share CPI Adj_Book
201606 229.400 241.018 314.295
201609 -447.600 241.428 -612.205
201612 295.769 241.432 404.531
201703 197.615 243.801 267.657
201706 322.000 244.955 434.074
201709 -1,118.667 246.819 -1,496.637
201712 -99.733 246.524 -133.590
201803 -212.400 249.554 -281.050
201806 -432.467 251.989 -566.716
201809 -177.762 252.439 -232.529
201812 182.387 251.233 239.724
201903 127.288 254.202 165.349
201906 75.925 256.143 97.881
201909 1.612 256.759 2.073
201912 -43.881 256.974 -56.387
202003 -73.437 258.115 -93.950
202006 -98.800 257.797 -126.553
202009 -109.304 260.280 -138.672
202012 -61.915 260.474 -78.492
202103 150.754 264.877 187.940
202106 144.896 271.696 176.103
202109 138.890 274.310 167.195
202112 123.879 278.802 146.722
202203 107.298 287.504 123.237
202206 97.278 296.311 108.408
202209 87.405 296.808 97.242
202212 85.669 296.797 95.314
202303 79.094 301.836 86.530
202306 66.010 305.109 71.441
202309 60.337 307.789 64.733
202312 53.882 306.746 58.004
202403 45.757 312.332 48.377
202406 28.906 314.175 30.382
202409 9.413 315.301 9.858
202412 6.854 315.605 7.171
202503 5.570 319.799 5.751
202506 1.173 322.561 1.201
202509 0.654 324.800 0.665
202512 0.431 324.054 0.439
202603 0.336 330.213 0.336

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-10.10 mean?
Theriva Biologics (TOVX) has a Cyclically Adjusted Book per Share of $-10.10 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Theriva Biologics and its competitors.
Is Theriva Biologics' Cyclically Adjusted Book per Share too high?
Theriva Biologics' current Cyclically Adjusted Book per Share is $-10.10. Overall, Theriva Biologics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' Cyclically Adjusted Book per Share compare to OSRH and PBM?
Theriva Biologics' Cyclically Adjusted Book per Share of $-10.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Theriva Biologics and its competitors. Theriva Biologics's current Cyclically Adjusted Book per Share is $-10.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (TOVX) has a current Cyclically Adjusted Book per Share of $-10.10. The current Cyclically Adjusted Book per Share is $-10.10. Theriva Biologics' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Theriva Biologics (TOVX), the current Cyclically Adjusted Book per Share is $-10.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theriva Biologics Business Description

Address 9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
26GF Score

Get the complete analysis for TOVX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price